LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Kura Oncology Inc

Fechado

SetorSaúde

5.66 -1.05

Visão Geral

Variação de preço das ações

24h

Atual

Mín

5.63

Máximo

5.85

Indicadores-chave

By Trading Economics

Rendimento

-38M

-57M

Vendas

-40M

14M

EPS

-0.66

Margem de lucro

-407.067

Funcionários

192

EBITDA

-48M

-65M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+353.75% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-18M

508M

Abertura anterior

6.71

Fecho anterior

5.66

Sentimento de Notícias

By Acuity

20%

80%

33 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Very Strong Bearish Evidence

Kura Oncology Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de jun. de 2025, 20:51 UTC

Ganhos

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 20:48 UTC

Conversa de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 de jun. de 2025, 20:46 UTC

Conversa de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 de jun. de 2025, 19:31 UTC

Conversa de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 de jun. de 2025, 19:19 UTC

Conversa de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 de jun. de 2025, 19:16 UTC

Conversa de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:57 UTC

Aquisições, Fusões, Aquisições de Empresas

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 de jun. de 2025, 18:42 UTC

Conversa de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 de jun. de 2025, 18:39 UTC

Conversa de Mercado
Ganhos

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 de jun. de 2025, 18:29 UTC

Conversa de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 de jun. de 2025, 18:18 UTC

Conversa de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 de jun. de 2025, 18:16 UTC

Conversa de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 de jun. de 2025, 17:16 UTC

Conversa de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 de jun. de 2025, 17:08 UTC

Ganhos

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 de jun. de 2025, 16:52 UTC

Aquisições, Fusões, Aquisições de Empresas

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 de jun. de 2025, 16:22 UTC

Ganhos

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 de jun. de 2025, 16:20 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

27 de jun. de 2025, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

27 de jun. de 2025, 15:59 UTC

Conversa de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 de jun. de 2025, 15:56 UTC

Conversa de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparação entre Pares

Variação de preço

Kura Oncology Inc Previsão

Preço-alvo

By TipRanks

353.75% parte superior

Previsão para 12 meses

Média 26 USD  353.75%

Máximo 40 USD

Mínimo 8 USD

Com base em 13 analistas de Wall Street que oferecem metas de preço de 12 meses para Kura Oncology Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

13 ratings

11

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

5.575 / 6.6Suporte e Resistência

Curto Prazo

Very Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

33 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.